While the pathophysiology of iMCD and TAFRO syndrome remains not fully understood, the proinflammatory cytokine interleukin-6 (IL-6) is both a central driver of disease pathogenesis and a key therapeutic target (17, 18). This evidence concerns the gene IL6 and Castleman-Kojima disease.